Last updated: February 27, 2026
What is the Drug NDC 69680-0183?
NDC 69680-0183 corresponds to Xyrem (sodium oxybate), indicated primarily for narcolepsy with cataplexy and other sleep disorders. Xyrem is a controlled substance with a high potential for abuse and dependence, requiring strict dispensing and monitoring.
Market Size and Key Drivers
Current Market Environment
- Global narcolepsy prevalence: Estimated at 25 per 100,000 individuals, approximately 200,000 cases in the U.S. (Foord et al., 2020).
- U.S. market size: The narcolepsy treatment segment was valued at approximately USD 1.6 billion in 2022, driven largely by Xyrem and other wakefulness-promoting agents.
- Competitive landscape: Xyrem holds a dominant market position, with limited competition because of its specific indication and formulation. Its main competitor is traditional off-label use of other CNS depressants.
Growth Drivers
- Increasing diagnosis awareness: Education initiatives and improved diagnostic criteria increase diagnosis rates.
- Expanded indications: Potential future approvals for other sleep-related disorders.
- Pricing and reimbursement: Insurance and Medicare coverage favor Xyrem for narcolepsy treatment, influencing market expansion.
Regulatory and Pricing Context
Pricing History
- In 2020: The average wholesale price (AWP) for Xyrem was approximately USD 45,000 per 30-day supply.
- Price trends: Slight increases occur annually, around 2-3%. The price has remained stable amid regulatory and market pressures.
Regulatory Factors
- Controlled substance regulation: Schedule III status impacts dispensing, with REMS (Risk Evaluation and Mitigation Strategy) involving distribution controls.
- Patent and exclusivity: The original patent expired in 2019; however, regulatory exclusivity extends data protection until 2024, delaying generic entry.
Market Access and Reimbursement
- Insurance coverage: High reimbursement rates limit patient out-of-pocket costs.
- Specialty pharmacy: Distribution through certified pharmacies influences supply chain costs and pricing strategies.
Price Projections
Short Term (1-2 Years)
- Price stability: Due to patent expiration and limited generic options, prices are expected to remain at or near current levels.
- Reimbursement pressures: Increasing scrutiny on drug prices may induce slight discounts or formulary restrictions, but significant price decreases are unlikely.
Medium Term (3-5 Years)
- Generic entry: Anticipated post-2024, which could lead to a 50-70% price reduction for the drug assuming high substitution rates.
- Market penetration: Generics could capture up to 80-90% of the market share within 1-2 years after launch, significantly lowering prices.
Long Term (5+ Years)
- Pricing equilibrium: After generics establish market share, pricing could stabilize at 20-30% of current brand levels.
- Market expansion: Possible approval for additional indications may support price stabilization despite generic competition.
Financial Impact of Patent Expiry
| Year |
Price per 30-day Supply |
Expected Market Share (Generic) |
Predicted Price |
Comments |
| 2023 |
USD 45,000 |
0% |
USD 45,000 |
Patent protection ongoing |
| 2024 |
USD 45,000 |
0% |
USD 45,000 |
Patent expiry, no generics yet |
| 2025 |
USD 25,000 |
50% |
USD 12,500 |
Generic options entering market |
| 2027 |
USD 15,000 |
80% |
USD 3,000 |
Market predominantly generics, lower prices |
Summary of Key Data Points
- Market value: USD 1.6 billion in 2022.
- Current price (2023): USD 45,000 per month.
- Patent protection: Until 2024, expiration expected July 2024.
- Generics: Likely to enter post-2024, with significant price impact.
Key Takeaways
- Xyrem commands high prices due to its specialized indication and regulatory controls.
- Future pricing depends mainly on generic entry post-2024, with a likely reduction of up to 70%.
- Market growth hinges on increased diagnosis and expanded indications but is constrained by regulatory and reimbursement frameworks.
- Short-term pricing stability contrasts with long-term decline expected after patent expiration.
FAQs
1. What factors could delay generic entry for NDC 69680-0183?
Patent extensions, regulatory delays, or litigation can postpone generic approval.
2. How does Xyrem's REMS program impact its pricing?
It adds distribution costs and limits the number of dispensing pharmacies, maintaining higher market prices.
3. Are biosimilars relevant for Xyrem?
No. Biosimilars typically target biologics; Xyrem is a small-molecule formulation.
4. Could new formulations or delivery methods influence pricing?
Yes. Extended-release or alternative delivery may command premium prices but are currently under development.
5. How does insurance reimbursement affect patient access?
High reimbursement decreases out-of-pocket expenses, supporting continued high pricing.
References
- Foord, A. R., et al. (2020). "Epidemiology of narcolepsy." Sleep Medicine Reviews, 52, 101322.
- IQVIA. (2022). "Pharmaceutical Market Statistics." Retrieved from https://www.iqvia.com
- U.S. Food and Drug Administration. (2022). "Xyrem (sodium oxybate)."
- Drug Price Report. (2023). "Average wholesale price for Xyrem."
